Explore more publications!
Maryland Healthcare Reporter
Got News to Share?

Maryland Healthcare Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Maryland Healthcare Reporter.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on September 22, 2025

Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index
September 22, 2025

Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index

Indeterminate GlobeNewswire
Fierce Biotech names Incyclix Bio a “Fierce 15” Biotech Company of 2025
September 22, 2025

Fierce Biotech names Incyclix Bio a “Fierce 15” Biotech Company of 2025

Indeterminate GlobeNewswire
Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed
September 22, 2025

Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed

Indeterminate GlobeNewswire
Crisis Text Line Acquires Aquí Estoy Chat; Plans to Expand Mental Health Support Across Spanish-Speaking Countries: Latin America, Spain, and the Caribbean
September 22, 2025

Crisis Text Line Acquires Aquí Estoy Chat; Plans to Expand Mental Health Support Across Spanish-Speaking Countries: Latin America, Spain, and the Caribbean

Indeterminate GlobeNewswire
Yatiri Bio Receives Grant to Advance Proteomics Interoperability in Cancer Research
September 22, 2025

Yatiri Bio Receives Grant to Advance Proteomics Interoperability in Cancer Research

Indeterminate GlobeNewswire
AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth
September 22, 2025

AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth

Indeterminate GlobeNewswire
WORK Medical Technology Group LTD Partners with Wuxi Branch of Ruijin Hospital-Shanghai Jiao Tong University School of Medicine to Develop AI-Applications in Healthcare
September 22, 2025

WORK Medical Technology Group LTD Partners with Wuxi Branch of Ruijin Hospital-Shanghai Jiao Tong University School of Medicine to Develop AI-Applications in Healthcare

Indeterminate GlobeNewswire
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
September 22, 2025

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

Indeterminate GlobeNewswire
NetraMark Initiates AI-Driven Collaboration in Glioblastoma Research
September 22, 2025

NetraMark Initiates AI-Driven Collaboration in Glioblastoma Research

Indeterminate GlobeNewswire
Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer
September 22, 2025

Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer

Indeterminate GlobeNewswire
Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline’s Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD
September 22, 2025

Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline’s Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

Indeterminate GlobeNewswire
CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe
September 22, 2025

CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe

Indeterminate GlobeNewswire
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
September 22, 2025

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

Indeterminate GlobeNewswire
Jushi Holdings Inc. Announces Favorable Modifications to Existing Manassas, VA Mortgage
September 22, 2025

Jushi Holdings Inc. Announces Favorable Modifications to Existing Manassas, VA Mortgage

Indeterminate GlobeNewswire
FOXO TECHNOLOGIES INC. ANNOUNCES CLOSING OF VECTOR BIOSOURCE INC. ACQUISITION
September 22, 2025

FOXO TECHNOLOGIES INC. ANNOUNCES CLOSING OF VECTOR BIOSOURCE INC. ACQUISITION

Indeterminate GlobeNewswire
New Peer Reviewed Publication of Combination Therapy in Vitiligo with STRATA Skin Sciences’ Excimer Laser and JAK Inhibitors Demonstrated Superior Safety and Unprecedented Response Rates, Providing Continued Validation of Personalized Medicine Approach
September 22, 2025

New Peer Reviewed Publication of Combination Therapy in Vitiligo with STRATA Skin Sciences’ Excimer Laser and JAK Inhibitors Demonstrated Superior Safety and Unprecedented Response Rates, Providing Continued Validation of Personalized Medicine Approach

Indeterminate GlobeNewswire
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
September 22, 2025

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

Indeterminate GlobeNewswire
AMN Healthcare Launches $400.0 Million Offering of Senior Notes
September 22, 2025

AMN Healthcare Launches $400.0 Million Offering of Senior Notes

Indeterminate GlobeNewswire
24/7 Market News: Kraig Labs Targets Eco Luxury Spider Silk Apparel Market
September 22, 2025

24/7 Market News: Kraig Labs Targets Eco Luxury Spider Silk Apparel Market

Indeterminate GlobeNewswire
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
September 22, 2025

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions